Some anaerobes and facultative anaerobes have been used in tumor-specific gene therapy by reason of their selective growth in tumors. In this work, we aimed to evaluate the anticancer efficacy of attenuated Salmonella typhimurium as a carrier to deliver the Escherichia coli purine nucleoside phosphorylase (ePNP) gene for GDEPT (gene-directed enzyme-prodrug therapy). A live attenuated purine-auxotrophic strain of S. typhimurium (SC36) was used to carry the pEGFP-C1-ePNP vector that contains a green fluorescent protein (GFP) and an ePNP gene under the control of the human cytomegalovirus (CMV) promoter. The function of the ePNP expression vector was confirmed in vitro using the enzymic conversion of 6-methylpurine 2 0 -deoxyriboside (MePdR) into 6-methylpurine. We also observed a high bystander effect induced by the ePNP/MePdR system with a very low proportion (1%) of ePNP-positive cells. The killing effect and increased apoptosis induced by SC/ePNP (SC36 carrying the ePNP expression vector) infection were detected by cytotoxicity assay and PI staining flow cytometry analysis, in combination with MePdR administration. Furthermore, SC/ePNP was administered orally into mice bearing melanomas or pulmonary tumors, and its anti-tumor effect was evaluated. When the tumor was huge (500 mm 3 ) at the beginning of MePdR administration, SC/ePNP plus MepdR significantly inhibited tumor growth by about 59-80% and prolonged survival of mice. Complete tumor regression and long-term cure were achieved by MePdR administration, even when the tumor was large (100 mm 3 ) at the beginning of MePdR treatment. Our data support a hopeful view that tumor-targeting SC36 could improve antitumor efficacy of the ePNP/MePdR system due to its preferential accumulation and anticancer activity in tumors.
Introduction
Current limitations of gene therapy for malignant tumors include lack of tumor-specific vector and insufficient gene delivery. 1 To resolve these problems, some anaerobes and facultative anaerobes have been considered as intriguing candidates to selectively target solid tumors. S. typhimurium, a facultative anaerobe, has been reported to be capable of both killing tumors and selectively expressing exogenous genes encoding therapeutic proteins. 2, 3 To increase its applicability for treatments, S. typhimurium was engineered to improve tumor-specific targeting as well as to reduce toxicity. [2] [3] [4] [5] [6] [7] Some properties of attenuated Salmonella strains are as follows: (a) high safety for systemic administration; (b) the tumor-to-normal tissue of bacterial accumulation at ratios ranging from 1000:1 to 10 000:1; (c) essential ability to deliver eukaryotic expression vectors to mammalian host cells in vitro and in vivo; (d) innate activity against tumors; (e) ease in growing, purifying and storing. [2] [3] [4] Of several GDEPT (gene-directed enzyme-prodrug therapy) systems, we were interested in the E. coli purine nucleoside phosphorylase (ePNP)/6-methylpurine 2 0 -deoxyriboside (MePdR) system described by Sorcher et al. 8 It has been reported that ePNP gene could convert MePdR into a toxic substance named 6-methylpurine (MeP). As prokaryotic PNP enzymes differ fundamentally in sequence, structure, and function from their eukaryotic counterparts, MePdR should be a poor substrate for mammalian PNP. [9] [10] [11] [12] [13] Therefore, expression of ePNP is able to kill a number of cancer cells in vitro when a small fraction of cells (for example, 0.1-3%) express this suicide gene, in combination with MePdR administration. 8, [14] [15] [16] [17] [18] As expression of suicide genes will not be achieved in all the tumor cells, a bystander effect is necessary to produce toxic metabolites to kill not only the positive cells but also the bystander cells. [19] [20] [21] The ePNP/ MePdR system differs from other GDEPT systems, because the toxic metabolites of this system will readily cross the cell membrane and not require direct cell-to-cell contact or the presence of a gap junction. 22 In previous papers, the ePNP/MePdR system has been reported to be an efficient suicide gene/prodrug system with significant antitumor activities on ovarian cancers, 17 gliomas, 23 prostate cancers, 24 melanomas, 25 pancreatic cancers, 26, 27 hepatomas 28, 29 and bladder tumors. 30 However, an exploitation of this method using attenuated Salmonella as a carrier to deliver the ePNP gene has never been attempted. To fully explore the potential anticancer effect of Salmonella-mediated ePNP gene combined with MePdR administration, we constructed a recombinant plasmid expressing the ePNP gene (pEGFP-C1-ePNP) and transformed it into a live attenuated purine-auxotrophic strain of S. typhimurium (SC36). Then, the function of the ePNP expression vector was confirmed in vitro using the enzymic conversion of MePdR into Mep. Furthermore, the bystander effect and the apoptosis efficiency of the ePNP/MePdR system were assessed in vitro by MTT assay and flow cytometry analysis. The in vivo antitumor activities were also addressed in terms of tumor growth and survival rate in mice with melanomas or pulmonary tumors.
Materials and methods

Construction of plasmid pEGFP-C1-ePNP
Full-length cDNA of purine nucleoside phosphorylase (EC2. 4.2.1, PNPase) gene (DeoD) was polymerase chain reaction (PCR)-amplified from E. coli DH5a genomic DNA. Genomic DNA preparation was performed as described. 31 Specific primers for PCR were designed according to the published sequences: sense primer, 5 0 -G GGAATTCGATGGCTACCCCACACATTAA-3 0 ; antisense primer, 5 0 -ATGTCGACTTACTCTTTATCGCCC AGCAG-3 0 . The EcoRI and SalI restriction site (underlined) were added to facilitate the PCR product (about 720 bp) inserting into the eukaryotic expression vector pEGFP-C1 (Clontech, Mountain View, CA, USA) by standard homologous recombination techniques. The pEGFP-C1 encodes a red-shifted variant of wild-type green fluorescent protein (GFP), which has been optimized for brighter fluorescence and higher expression in mammalian cells. The plasmid constructions were confirmed by DNA sequencing.
Bacterial strains and media
The auxotrophic S. typhimurium LB5000 (LT2Trp Met Erpsl flaA R-M þ ) and the SL3261 (WARY hisG46 aroA del 407 Fusaricres, R þ M þ ) were provided by Bruce AD Stocker (Professor of Stanford University School of Medicine, Stanford, CA). A novel purine-auxotrophic mutant SC36 (his G aro A cys pur I) with a low residual virulence was gained by DES mutagenesis of SL3261, as described previously. 32 Bacterial strains were routinely grown at 37 1C in LB broth or agar supplemented with kanamycin (50 mg ml À1 ) when it is required. The pEGFP-C1 and pEGFP-C1-ePNP were first transformed into LB5000 using electrotransformation in cuvettes (0.2 cm electrode gap, Eppendorf) with a single pulse of 12.5 kV cm À1 (2.5 kV, 200 O, 25 mF). After amplification of the colony, the plasmids were extracted from the transferred LB5000 (3S Spin Plasmid Miniprep Kit V 3.1, Biocolors) and then introduced into SC36 (in the same fashion as for LB5000) to generate SC/pEGFP and SC/ ePNP, respectively, bryonic kidney (HEK) cell line. 33 were used for cytotoxicity assay 34 and PI staining flow cytometry analysis. 35 
Cells
Stable positive cell lines and functional tests
The cell lines were transfected with pEGFP-C1 or pEGFP-C1-ePNP (Lipofectamine 2000, Invitrogen, Carlsbad, CA, USA) and selected with G418 at a concentration of 400 mg ml
À1
. Fresh media with G418 were replaced every 3 days. Fifteen days after the cell culture, the cell clones with G418 resistance (named LL/ ePNP, B16F10/ePNP, LL/pEGFP and B16F10/pEGFP, respectively) were obtained. Resistant clones were selected and the ePNP expression of them was monitored by RT-PCR. The positive clones highly expressing ePNP were selected for observing bystander effect by MTT assay 36 and analyzing enzymic conversion by highpressure liquid chromatography. 8 Bacterial distribution in vivo after oral administration Four-week-old female C57BL/6 mice were obtained from BK Company (Shanghai, China). Tumor xenografts were established by subcutaneous inoculation of tumor cells (5 Â 10 6 cells) into the right flanks of mice. When the tumors had reached a mean volume of approximately 80-100 mm 3 , mice were fed with 1 Â 10 9 c.f.u. of SC/ pEGFP. At different time points, three mice in each group were killed respectively, and their tumors, livers, spleens and kidneys were excised, weighed and homogenized in 2 ml of ice-cold, sterile PBS. The bacteria were quantified by plating serial dilutions of the homogenates onto LB agar plates containing kanamycin (50 mg ml
). Subsequently, the plates were incubated overnight at 37 1C and the bacterial colonies were counted.
RT-PCR analysis for gene expression in tumors
The EGFP mRNAs in the tumors of SC/pEGFP-treated mice were determined by RT-PCR. At different time points, total cellular RNA was isolated from the tumor tissues (TRIzol reagent, Invitrogen) and reverse-transcribed into cDNA (AccessQuick RT-PCR System, Promega). The cDNA was amplified by PCR to determine b-actin and EGFP mRNA expressions. Specific primers are described above.
Analysis of antitumor effect in vivo
To eliminate enteric flora, all mice were fed with sterilizing water containing neomycin (5 g l À1 ), streptomycin (5 g l
À1
) and penicillin (5 U ml
). After the first 2 weeks of antibiotic therapy, the animals were inoculated subcutaneously with 5 Â 10 6 murine tumor cells. When the tumors reached a mean volume of approximately 80-100 mm 3 , mice were randomly grouped (n ¼ 5 animals per group) and fed with sterilizing water without antibiotics. All SC/ePNP-treated mice received 1 Â 10 9 c.f.u. of SC/ ePNP and control mice received SC/pEGFP or buffer only. For bacteria colonization, all Salmonella-treated mice were fed with sterilizing water containing kanamycin (800 mg l À1 ) the day before or during the study. Subsequently, intraperitoneal injections of MePdR (30 mg per kg body weight) were administered according to two testing schedules. According to the first schedule, MePdR treatments were started 7 days after bacterial administration, when the mean tumor volume of tumors was over 500 mm 3 . According to the second schedule, MePdR treatments were started 48 h after bacterial administration, when the mean tumor volume of tumors was about 100 mm 3 . All blank mice received 0.9% normal saline solution. Tumor diameters were measured at regular intervals with calipers, and the tumor volume in mm 3 was calculated by the formula: volume ¼ 1/2 Â length Â width 2 . Survival rate was monitored after bacteria infection. Mice bearing LL/2 mouse Lewis lung carcinomas were killed when tumors reached 5500 mm 3 or before if they showed a sign of distress. Mice bearing B16F10 murine melanomas were killed when tumors reached 4000 mm 3 or before if they showed a sign of distress. These time points were defined as survival time.
Statistical analysis
Statistical analysis of the data was achieved by using Student-Newman-Keuls and log-rank test for survival analysis (Primer statistical software; SPSS Base 10.0. for Windows, SPSS Inc., Chicago, IL). The findings were regarded as significant if two-tailed P-values were o0.05.
Results
Functional tests of pEGFP-C1-ePNP in vitro
The function of the ePNP expression vector (pEGFP-C1-ePNP) was confirmed by RT-PCR after SC/ePNP infection in vitro. SC/ePNP-infected cells expressed high level of ePNP mRNAs ( Figure 1 ) and showed a strong sensitivity to MePdR ( Figure 2 ). Moreover, the ratio of MePdR conversion in the supernatants of ePNP-positive cells was 100% after 96 h ( Figure 5 ), indicating that plasmid pEGFP-C1-ePNP construction was functional. ), parental or SC/pEGFPinfected cells were resistant to MePdR, with IC 50 was calculated as the concentration of drug which inhibits cell growth by 50%. In contrast, SC/ePNP-infected cells were susceptible to MePdR, with IC 50 lower than 0.5 mg ml À1 (Figures 2a and b) . At the concentration of 10 mg ml À1 MePdR, the sensitivity of the infected cells to MePdR was time dependent. The prodrug treatments led to about 20% of cell death after 24 h and 95% of cell death after 96 h, respectively (Figures 2c and d) .
Effects of SC/ePNP increasing the spontaneous apoptosis of cells
The apoptosis results showed that SC/ePNP treatment increased the spontaneous apoptosis of the infected cells compared with the control cells at different concentrations of MePdR (ranging from 0 to 0.5 mg ml À1 ) ( Figure 3 ). The greatest increase in the number of apoptosis cells was at the final concentration of 0.5 mg ml À1 MePdR, and the ratio was 38.80% for LL/2 lung carcinomas cells and 26.42% for B16F10 melanomas cells.
High level of bystander effect
In the absence of ePNP-positive cells, the growth of parental cells was not affected even when the concentration of MePdR reached 10 mg ml
À1
. At the concentration of 1 mg ml À1 MePdR, the significant bystander effect could be detected even with a very low proportion (1%) of ePNP-positive cells. These results indicated that a high bystander effect was achieved (Figure 4 ).
MePdR conversion
The ratio of MePdR conversion in the supernatants of ePNP-positive cells was no more than 30% after 24 h, and it was 90% for LL/2 cells and 77% for B16F10 cells after 48 h. Ninety-six hours after the addition of MePdR, only Mep was detected in the supernatants of ePNP-positive cells. These results indicated that the PNP enzyme converted MePdR into Mep by means of a timedependent pattern ( Figure 5 ).
Bacterial distribution in murine tissues
We found that oral administration with 1 Â 10 9 c.f.u. of attenuated Salmonella (SC36) was most effective for the bacterial accumulation in the tumors ( Figure 6 ). 
Therefore, this dose was used for further experiments in vivo. The kinetics of bacterial distribution after oral administration was detected to be a time-dependent pattern. Significant accumulation of SC/pEGFP in the tumors could retain for at least 14 days, while a peak level was observed at day 7 and the tumor-to-normal tissue ratios were as high as 10 000:1 (Figures 6a and b) . As shown in Figure 6c , the EGFP expression in tumor tissues gradually declined from days 7-14. Taken together, these results showed that SC/pEGFP, when administrated to mice bearing established tumors, preferentially accumulated and retained in large amounts in tumors for at least 14 days.
Anticancer efficacy in vivo
As shown in Figure 7b , tumor growth of mice bearing LL/ 2 lung carcinomas was significantly retarded by Salmonella-mediated ePNP/MePdR system according to the first schedule. There was no statistical difference between four groups (PBS-treated, MePdR-treated, SC/pEGFPtreated and SC/ePNP-treated groups) at each time point during the experiments. The mean tumor volume of mice treated with SC/ePNP plus MePdR was lowered by 59, 69, 73, 77 and 80%, compared with that of mice treated with SC/pEGFP plus MePdR (P40.05, no statistical difference), SC/ePNP (P ¼ 0.02), MePdR (P ¼ 0.035), SC/ pEGFP (P ¼ 0.044) and PBS (P ¼ 0.001), respectively. Moreover, the mean tumor volume of mice treated with SC/pEGFP plus MePdR was lowered by 45, 34 and 51%, compared with that of mice treated with SC/pEGFP (P40.05, no statistical difference), MePdR (P40.05, no statistical difference) and PBS (P ¼ 0.05), respectively. As shown in Figure 7c , SC/ePNP plus MePdR also In conclusion, both SC/pEGFP and SC/ePNP could significantly suppress tumor growth, whereas the latter one had stronger antitumor effects than the former one, in combination with MePdR administration. When the tumor was huge (500 mm 3 ) at the beginning of MePdR administration, SC/ePNP plus MePdR significantly inhibited tumor growth by about 59-80% and prolonged survival of mice. Complete tumor regression and longterm cure were achieved by MePdR administration, even when the tumor was large (100 mm 3 ) at the beginning of prodrug treatment.
Discussion
This is the first report to exploit the anticancer efficacy of attenuated S. typhimurium as a carrier to deliver the E. coli purine nucleoside phosphorylase (ePNP) gene for GDEPT. In the work described here, we used an attenuated purine-auxotrophic strain of S. typhimurium (SC36) with a low residual virulence, gained by DES mutagenesis of SL3261. This attenuated Salmonella strain has lower toxicity and essential ability to deliver eukaryotic expression vectors to mammalian host cells. In view of these merits of SC36, we wondered whether the treatment of attenuated Salmonella could function as an enhancer for the ePNP/MePdR system to retard or stop tumor growth in mice. The infection of bacteria in tumors was recognized as early as 1868. Subsequently, tumor-targeted attenuated bacterial strains, such as S. typhimurium, Clostridium and Bifidobacterium, have been developed as antitumor agents with the responsibility of preferentially accumulating within tumors and inhibiting tumor growth. 2, 37, 38 Although they possess properties of selective replication within tumors, tumor retardation and gene delivery, the mechanisms contributing to their initial infection and gene delivery to tumors are not completely understood. Invasion of bacterial carrier strains into host cells has been shown to be important in cellular mechanisms of bacteria-mediated delivery. 39 It is possible that the Salmonella carrier strains are lysed within the phagolysosome, resulting in intraphagosomal release with subsequent transfer of plasmid DNA into the cytosol. Recently, Sam and colleagues 40 reported a simple framework for the intensity of intracellular infection and developed novel generic guidelines for the design of bacterial combination therapies. In our work, we observed preferential accumulation of SC36 within implanted tumors and SC36-mediated gene expressions in vitro and in vivo (Figures 1 and 6 ). Using two murine tumor models, we demonstrated that orally administered SC/pEGFP preferentially accumulated and amplified within implanted tumors, achieving the tumor-to-normal tissue ratio of 10 000:1 at day 7 (Figures 6a and b) . Therefore, our data, combined with those results reported previously, 6 suggested that SC36 was inclined to survive in tissues, which were hypoxic and provided more nutrients to it. These observations prompted us to explore whether SC36 carrying the ePNP expression vector was capable of both targeting tumor cells and suppressing tumor growth, in combination with MePdR administration.
In the MTT assay described here, parental or SC/ pEGFP-infected cells were resistant to MePdR, whereas SC/ePNP-infected cells were susceptible to MePdR (Figures 2a and b) . These findings suggested that SC36 could act as an antitumor agent to deliver proteins responsible for metabolizing chemotherapeutic MePdR directly to tumors. When the final concentration of MePdR was 10 mg ml À1 , the sensitivity of SC/ePNPinfected cells to MePdR was time dependent (Figures 2c  and d) . The results in Figure 5 provided evidence that enzymic conversion of MePdR into Mep was detected to be time dependent, which might relate to the gradual production of PNPase. Previous studies 41 mentioned that the intratumoral half-life of MeP was long (424 h), whereas the half-life of MePdR in serum was short (about 20 min). Using high-pressure liquid chromatography, we found that the half-life of MePdR in ePNP-positive cells was more than 24 h. Our data suggested the possibility that gradual ePNP expression of the positive cells might delay the complete catabolism of MePdR. In addition, PI staining results showed that the ePNP/MePdR system increased the spontaneous apoptosis of tumor cells (Figure 3) , consistent with those results reported previously. 18 We also observed a high bystander killing effect induced by the ePNP/MePdR system, with a very low proportion (1%) of SC/ePNP-infected cells (Figure 4) . The data presented here indicated that the ePNP/MePdR system could increase the spontaneous apoptosis of the tumor cells, and that its killing effect to the bystander cells was caused by a high bystander effect.
In this study, the MePdR treatments were administered in vivo according to two testing schedules. When the The continuous loss of recombinant plasmids during cell divisions may be one of the mechanisms. 42 Multiple administrations of the bacteria may be important to prolong gene expression and increase antitumor activity. 43 Furthermore, this combined approach could be improved by using cytokines (for example, IL-12), which have the capacity to induce the production of INF-gamma to achieve the inhibition of tumor growth. Alternatively, combination with other therapeutic strategies, such as radiotherapy, may be more effective for tumor regression. 44 Antitumor effects should be long lasting by reason of the ability of the bacteria to colonize and replicate in the tumor tissues. Although SC36 is effective to deliver plasmids carrying exogenous genes, the continuous loss of recombinant plasmids during cell divisions was observed. To achieve efficient colonization of Salmonella and suppression of gut microbes, an antibiotic treatment was used to reduce competing microbes. To make SC36 safer for clinical trials, it should be important to develop tumor-specific expression vectors. Deharvengt et al. 27 examined the feasibility of a tumor-specific targeting strategy to treat pancreatic cancer by using the human CEA and MUC1 promoters. Cai et al. 29 demonstrated the killing effect of PNP/MePdR suicide gene system driven by an AFP promoter AF0.3 on AFP-positive hepatoma cells. Mengesha et al. 45 developed a hypoxia-inducible promoter system and found that it could confine gene expression strictly to the tumors. Therefore, the use of tumor-specific gene promoters is an attractive option for Salmonella-mediated gene delivery.
It was detected that SC/pEGFP plus MePdR could retard tumor growth in vivo. But this effect was not seen in vitro. As the cells were washed and replenished with antibiotic media to eliminate external bacteria after infection in vitro, it is possible that internal bacteria might be lysed in vitro within the phagolysosome. The difference between the in vitro and the in vivo results indicates that Salmonella may exert multiple efforts for in vivo infection. On the one hand, attenuated Salmonella aims to infect more tumor cells and deliver the ePNP gene in the process of proliferation, which could facilitate the production of PNPase with the responsibility of metabolizing the prodrug. On the other hand, the PNP gene of external Salmonella may convert the nucleoside prodrug into a toxic substance to kill solid tumors. In addition, the infection of the attenuated Salmonella could stimulate immune responses and produce a trace of immune substances, such as cytokine and TNF-a. These synergistic antitumor properties suggest that tumor-targeting Salmonella could be promising to improve the killing effect of suicide gene/prodrug system. As substantial weight loss, limiting lethality or other toxicities were not observed in these experiments, our data supported the idea that Salmonella-mediated gene therapy was safe in murine models. Therefore, all results led us to combine these antitumor treatments together to achieve a more promising effect.
